Stocks Health care LEGN
NASDAQ · Health careLegend Biotech Corp (LEGN)
Legend Biotech Corp reported revenue of $1B in fiscal 2025, up 64.0% from a year earlier. It posted a net loss of $296.8M. In fiscal 2025 capital spending exceeded operating cash flow by $128.8M. At December 31, 2025 it held $901.9M in cash against $319.1M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 10, 2026.
Key facts about Legend Biotech Corp
- Net worth
- Legend Biotech Corp has a market value (market cap) of $4.7B at the latest share price, and shareholders' equity of $1B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1B (+64.0% year on year), with a net loss of $296.8M.
- Cash flow
- In fiscal 2025 operations used $100.2M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 10, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Legend Biotech Corp does
Legend Biotech Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LEGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1B | -$296.8M | -$0.81 | -$128.8M |
| 2024 | $627.3M | -$177M | -$0.48 | -$158.1M |
| 2023 | $285.1M | -$518.3M | -$1.47 | -$413.4M |
| 2022 | $117M | -$446.3M | -$1.40 | -$222.2M |
| 2021 | $68.8M | -$403.6M | -$1.43 | -$240.7M |
| 2020 | $75M | -$266.4M | -$1.13 | -$249.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where LEGN ranks in Health care
Latest SEC filings
What Legend Biotech Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026
- October 15, 2026
- October 13, 2026
- October 7, 2026
- September 25, 2026
- September 24, 2026
- September 15, 2026
- September 14, 2026
- August 18, 2026
Insider trades
What the people running Legend Biotech Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $308.6K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 29, 2026 | Sanders Corazon (Corsee) D.Director | Sold | 27,370 | $258.9K |
| September 24, 2026 | Sanders Corazon (Corsee) D.Director | Received as pay | 20,986 | - |
| September 24, 2026 | Heyman Tomas J.Director | Received as pay | 20,986 | - |
| September 24, 2026 | Ji Darren XiaohuiDirector | Received as pay | 28,330 | - |
| September 24, 2026 | Casey Patrick JohnDirector | Received as pay | 20,986 | - |
| September 24, 2026 | Salovey PeterDirector | Received as pay | 28,330 | - |
| September 24, 2026 | Mao LiDirector | Received as pay | 20,986 | - |
| September 21, 2026 | Santos Carlos EChief Financial Officer | Received as pay | 19,676 | - |
Who owns LEGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 15% | August 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 218 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 29,093,899 | +3,397,159 |
| Deerfield Management Company, L.P. | 8,137,638 | +450,000 |
| Montanova Capital, LLC | 7,070,000 | -511,029 |
| Hhlr Advisors, Ltd. | 5,984,550 | 0 |
| BlackRock, Inc. | 4,726,534 | +41,991 |
| Westfield Capital Management Co LP | 4,430,063 | -1,333,412 |
| Assenagon Asset Management S.A. | 3,830,112 | new |
| Goldman Sachs Group Inc | 3,662,315 | +2,198,203 |
| Point72 Asset Management, L.P. | 3,076,124 | -809,893 |
| Kynam Capital Management, LP | 3,001,205 | +1,424,910 |
| Artisan Partners Limited Partnership | 1,559,441 | -695,047 |
| State Street Corp | 1,498,704 | +332 |
| Capital International Investors | 1,420,654 | +772,804 |
| Morgan Stanley | 1,394,531 | +791,284 |
| Soleus Capital Management, L.P. | 1,205,000 | new |
| Davern Capital Partners, LP | 1,191,522 | -123,226 |
| Driehaus Capital Management LLC | 1,158,808 | new |
| Renaissance Technologies LLC | 1,000,200 | +478,400 |
| Ghisallo Capital Management LLC | 1,000,000 | new |
| Matthews International Capital Management LLC | 917,266 | -8,654 |
Insiders
10 insiders reported holding 1,808,294 shares in total, about $43.9M at the last price.
| Holder | Shares |
|---|---|
| Zhang IngridChief Executive Officer | 1,131,860 |
| Huang YingChief Executive Officer, Director | 238,490 |
| Ji Darren XiaohuiDirector | 92,103 |
| Casey Patrick JohnDirector | 69,590 |
| Mao LiDirector | 65,316 |
| Salovey PeterDirector | 55,096 |
| Heyman Tomas J.Director | 53,720 |
| Sanders Corazon (Corsee) D.Director | 52,731 |
| Bash AlanInterim CEO | 35,142 |
| Santos Carlos EChief Financial Officer | 14,246 |
Questions about LEGN
What does Legend Biotech Corp do?
Legend Biotech Corp is a company in the Health care sector, listed on NASDAQ as LEGN. Its shares trade on NASDAQ under the ticker LEGN.
What is Legend Biotech Corp's net worth?
Legend Biotech Corp has a market value (market cap) of $4.7B at the latest share price, and shareholders' equity of $1B on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Legend Biotech Corp profitable?
No. In fiscal 2025 it reported a net loss of $296.8M on revenue of $1B.
How much revenue does Legend Biotech Corp make?
In fiscal 2025 Legend Biotech Corp reported revenue of $1B. That is 64.0% more than a year earlier.
When did Legend Biotech Corp last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 10, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the passive stake changed from November 5, 2026.
Similar companies
Compare LEGN with
Follow LEGN
Get an email when Legend Biotech Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Legend Biotech Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.